Memantine XR
PreclinicalSmall molecule
Memantine XR is one of 36 small molecule programs targeting Autism. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
37 competitors in Autism
#DrugCompanyPhaseTrials
1Savella
AbbVieApproved
Vyvanse
TakedaApproved
Abilify
OtsukaApproved
Lioresal
NovartisApproved
Depakote
AbbVieApproved
Risperdal
WWim Janssens
Approved
Minocin
TTriax
Approved
Strattera
MMap77
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Memantine XR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSheppard Pratt Health System